Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. - sprookjes - yvandenbroek - TriplyDB

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.

http://www.wikidata.org/entity/Q42716993

about

Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series)Is there a new dawn for selective mineralocorticoid receptor antagonism?Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney.30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development.Interfering with mineralocorticoid receptor activation: the past, present, and future New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseas Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628.Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?Microwave-assisted protection of primary amines as 2,5-dimethylpyrroles and their orthogonal deprotection.Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy.Targeting the mineralocorticoid receptor in cardiovascular disease.Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte.Mineralocorticoid receptor modulators: a patent review (2007 - 2012).Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.Aldosterone excess and resistant hypertension: investigation and treatment.Novel drug mechanisms in development for heart failure.Newest additions to heart failure treatment.Novel RAAS agonists and antagonists: clinical applications and controversies.New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.New medical therapies for heart failure.Future drug discovery in renin-angiotensin-aldosterone system intervention.Treatment of Hyperkalemia in Heart Failure.Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence.Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.Deletion of the Mineralocorticoid Receptor in Myeloid Cells Attenuates Central Nervous System Autoimmunity.Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure.Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.

P2860

Q26746907-37159A58-F326-4891-8B7E-3C021932547F Q26996385-A2C0E68D-9944-4031-9E64-323F1F94837A Q27013946-60213DF5-48D5-4B0B-92F6-81ECA36C5AB8 Q27027792-D2386437-3C32-4FDF-B3E6-C7357AB8DF44 Q30248429-A7AF59AD-89CA-4A32-B9BF-75EA3B99C7B1 Q33846431-F8D31FE7-5549-4450-9C44-0561F0644520 Q34019947-C312F7B0-6C5A-4EBE-987A-4EB2E1706CCB Q34384580-649D342B-5652-4737-BEBF-374DD7DE17AC Q34462504-ED8A374B-5A5B-4E8B-A260-3E590F15AE41 Q35877719-77155E54-799C-4E52-BA6A-8CAC37AB0255 Q36206559-4628E87A-233D-42FB-B9BD-452D351F61E6 Q36437145-BA9C468C-51B0-41F7-9A15-62D6FBA55C9A Q37094366-FC94EA63-9755-42E0-8A9B-5D99F89107F7 Q37098407-505C1D07-8F73-4B94-BEC6-8A00F7EE8D2F Q37347190-7BD9E536-15CC-4BDA-A840-1BAD50C6E143 Q37363526-8C1D8979-CB64-44CB-8C93-8FD6C0BB63E8 Q37720499-712098D4-84D6-4761-973B-3A9DF6B7E9F9 Q38074488-EF74BEF6-3BCE-4CB8-987B-73BEC18C88DB Q38119546-1CB5D959-FB88-40F7-8399-3F28F62AC490 Q38161538-F8BD1751-930E-4DA8-90EF-C8CF5C0A96CA Q38181208-DC925AB9-60C7-4830-978C-9AA7987702AA Q38208961-56CF9108-A784-4B32-9752-F7E9D39454A1 Q38209074-F242893C-5192-48C1-9DD9-10B146975C88 Q38225739-186AFD19-E498-4551-8DC6-25B50A5F1872 Q38349798-ED3E5DE2-851A-490D-B99E-8CEFF88DA6FE Q38429870-1B950982-0AB1-4F88-A1AA-59983683D674 Q38533385-5BD381FA-AA78-4998-9EE9-D123867BD2E0 Q38594785-4306767B-84DA-4AA7-B490-1FA120868D63 Q38679303-CE58B448-42D3-420A-8E29-6DDBAD7DB592 Q38705827-25306D0C-DD46-4C04-AB55-7958E546E823 Q38750210-3A9855A6-E827-4E40-95DA-524D0029FEA6 Q38766590-B7E389AB-6050-4DAB-BC83-F02C807C9692 Q38817871-23D21E9C-C134-4AD2-84A8-13DA4DDC7C2B Q38850114-5AA8FAED-D942-45C7-A6AB-D6C97C41A1CF Q38965181-6DFFF8FF-F489-4D93-B3C5-D39FA0D3A0BD Q39199991-83166EC9-34A1-4BD2-830B-555729692CCC Q41677231-20D6C2E6-60C1-4071-B92B-F17CEC574F10 Q47120039-5AE73A97-7A24-4C28-A962-88D3EEDB3D63 Q47575429-D96B53EF-5361-4415-9CEF-EAB31F3BF369 Q51293660-2BEFC734-5212-41E1-9369-812D09312EF1

P2860

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.

http://www.wikidata.org/entity/Q42716993

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.

@en

Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.

@nl

type

label

Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.

@en

Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.

@nl

prefLabel

Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.

@en

Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.

@nl

P1433

Q42716993-32D0669F-5EFC-4B8B-9A09-D6DD4C9C7A5E

P1476

Q42716993-005DBC41-DC03-427C-A742-4172D541702F

P2093

Q42716993-0F678377-AAAB-4B62-A614-5A47C051FC20

Q42716993-4C3648BD-387B-42F1-96A7-C8A858E67C07

Q42716993-5387CAB5-D5D0-46DA-A60B-34399822DC61

Q42716993-62B096C4-D13F-467C-905E-F7DC028C997D

Q42716993-69108473-BC66-4AF2-BB70-A097C8D7F19E

Q42716993-92DA3A29-C9D6-4A82-916B-B0ED4524835E

Q42716993-93658FF2-EC3E-4F5A-8ABA-EC2DC20EB175

Q42716993-B28EEAB3-155C-46A8-B78D-1AE8F76910A3

Q42716993-C06B554B-0098-4A61-A750-B447BD0AD717

Q42716993-C2376237-6A34-4E32-8790-319261F74954

P2860

Q42716993-04753C1F-6891-4EDF-B6F5-601A8F4EDCA8

Q42716993-07469E64-2B94-4E53-AB22-50263C65FC7A

Q42716993-21DAC269-AFFB-4651-9156-ACAFC1C05B44

Q42716993-33976E88-12D4-461E-9B3C-DF1374216384

Q42716993-39DFC0F4-19FF-4CBA-A9D9-854565E9FD4C

Q42716993-4C6B6B27-D726-4643-94F0-1A7F960C976C

Q42716993-51B7D1EA-FD76-403B-A546-2AEB58FB09E1

Q42716993-53C30016-E503-4AD1-B8E8-FCF8C25AA659

Q42716993-542A45EE-2FF9-4609-8437-B29EEE9D9A84

Q42716993-60768D08-54BE-4BB7-B985-F5B2A37F62AA

P304

Q42716993-0DA5236E-DD90-481E-A54A-5CF9284A64E7

P31

Q42716993-48B150B4-1F58-4E6E-AA8F-1A6580D54223

P356

Q42716993-8F1338A9-DB0E-4354-B4D2-1EC029B5FB4C

P433

Q42716993-911B7256-0693-4B5B-9731-336C9B5211A2

P478

Q42716993-055F410F-CBC3-4F2A-9952-057F8DC4244E

P577

Q42716993-26A67B1B-3843-4437-90A9-E00FFEF31BA3

P698

Q42716993-4703775C-BF10-47DB-BEF6-1BCB55A8D1F5

P356

P1433

P1476

Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.

@en

P2093

Adam Nitsche

http://www.w3.org/2001/XMLSchema#string

Alexander Hillisch

http://www.w3.org/2001/XMLSchema#string

Alexander Kuhl

http://www.w3.org/2001/XMLSchema#string

Heike Gielen-Haertwig

http://www.w3.org/2001/XMLSchema#string

Heike Heckroth

http://www.w3.org/2001/XMLSchema#string

Holger Paulsen

http://www.w3.org/2001/XMLSchema#string

Jens-Kerim Ergüden

http://www.w3.org/2001/XMLSchema#string

Joachim Mittendorf

http://www.w3.org/2001/XMLSchema#string

Johannes Platzek

http://www.w3.org/2001/XMLSchema#string

Karl-Heinz Schlemmer

http://www.w3.org/2001/XMLSchema#string

P2860

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

Mechanisms of ligand specificity of the mineralocorticoid receptor

Structural basis of spirolactone recognition by the mineralocorticoid receptor

Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.

Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget.

Pharmacologic profile of amlodipine.

P304

1385-1403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CMDC.201200081

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22791416

http://www.w3.org/2001/XMLSchema#string